🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Serotonin Control of Impulsivity in Tourette Disorder

RecruitingPhase 2Ages 18 Years - 65 YearsAllHospices Civils de Lyon
NCT05942716 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A re

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
* Inclusion Criteria \* : * Male or Female * Diagnosed with a Tourette Disorder following the DSM-5 * Age between 18-65 years * Member of a social security scheme in France * Freely-given informed consent to participate to this study (written form) * With a current treatment by aripiprazole already scheduled * With Tics compatible with TEP/fMRI exams * Having (for women only) effective contraception throughout participation in the study. Exclusion Criteria \* : * Male or Female * A serious not controlled psychiatric comorbidity * A serious, evolving or debilitating pathology with a potential influence on the study * Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin) * Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia) * Women breastfeeding * Protected or restricted person (administratively or in judicial terms) * Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study * Do not speak french
💊

What it tests

  • Administration of a PET radiotracer
📍

Where

2 sites
Service de neurologie C Hôpital neurologique Pierre Wertheimer/GHE Hospices Civils de Lyon
Bron, France
Centre de Référence Syndrome Gilles de la Tourette Département de Neurologie Pôle des Maladies du Système Nerveux Hôpital de la Pitié-Salpêtrière
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy